Concord Medical Services Holdings Limited Logo

Concord Medical Services Holdings Limited

CCM

(1.8)
Stock Price

5,53 USD

-16.48% ROA

3.57% ROE

-0.43x PER

Market Cap.

328.537.871,48 USD

-173.82% DER

0% Yield

-75.95% NPM

Concord Medical Services Holdings Limited Stock Analysis

Concord Medical Services Holdings Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Concord Medical Services Holdings Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (47.56%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.19x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-174%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

5 ROA

The stock's ROA (-16.48%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-7) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Concord Medical Services Holdings Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Concord Medical Services Holdings Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Concord Medical Services Holdings Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Concord Medical Services Holdings Limited Revenue
Year Revenue Growth
2008 171.789.000
2009 292.436.000 41.26%
2010 389.524.000 24.92%
2011 450.125.000 13.46%
2012 672.056.000 33.02%
2013 974.577.000 31.04%
2014 606.883.000 -60.59%
2015 616.485.000 1.56%
2016 455.042.000 -35.48%
2017 330.977.000 -37.48%
2018 190.898.000 -73.38%
2019 198.363.000 3.76%
2020 223.011.000 11.05%
2021 485.633.000 54.08%
2022 762.844.000 36.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Concord Medical Services Holdings Limited Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Concord Medical Services Holdings Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 18.869.000
2009 29.821.000 36.73%
2010 70.008.000 57.4%
2011 114.399.000 38.8%
2012 71.698.000 -59.56%
2013 105.114.000 31.79%
2014 53.576.000 -96.2%
2015 132.952.000 59.7%
2016 205.908.000 35.43%
2017 237.646.000 13.36%
2018 291.854.000 18.57%
2019 315.134.000 7.39%
2020 294.823.000 -6.89%
2021 347.746.000 15.22%
2022 762.828.000 54.41%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Concord Medical Services Holdings Limited EBITDA
Year EBITDA Growth
2008 140.382.000
2009 168.327.000 16.6%
2010 182.239.000 7.63%
2011 152.214.000 -19.73%
2012 218.511.000 30.34%
2013 207.213.000 -5.45%
2014 220.881.000 6.19%
2015 67.874.000 -225.43%
2016 68.293.000 0.61%
2017 -72.126.000 194.69%
2018 -211.557.000 65.91%
2019 -263.627.000 19.75%
2020 -206.429.000 -27.71%
2021 -331.404.000 37.71%
2022 780.672.000 142.45%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Concord Medical Services Holdings Limited Gross Profit
Year Gross Profit Growth
2008 126.192.000
2009 204.875.000 38.41%
2010 266.824.000 23.22%
2011 290.709.000 8.22%
2012 333.898.000 12.93%
2013 387.628.000 13.86%
2014 332.321.000 -16.64%
2015 263.149.000 -26.29%
2016 168.499.000 -56.17%
2017 97.998.000 -71.94%
2018 19.762.000 -395.89%
2019 -15.830.000 224.84%
2020 13.083.000 221%
2021 -56.897.000 122.99%
2022 -532.428.000 89.31%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Concord Medical Services Holdings Limited Net Profit
Year Net Profit Growth
2008 79.069.000
2009 124.827.000 36.66%
2010 129.400.000 3.53%
2011 -215.003.000 160.19%
2012 129.802.000 265.64%
2013 88.355.000 -46.91%
2014 124.709.000 29.15%
2015 -79.438.000 256.99%
2016 -261.867.000 69.66%
2017 -284.320.000 7.9%
2018 -234.875.000 -21.05%
2019 -352.092.000 33.29%
2020 -404.029.000 12.85%
2021 -522.672.000 22.7%
2022 -1.003.744.000 47.93%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Concord Medical Services Holdings Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 -26
2009 2 2600%
2010 3 50%
2011 -5 150%
2012 3 300%
2013 2 -100%
2014 3 50%
2015 -2 300%
2016 -6 83.33%
2017 -7 0%
2018 -5 -20%
2019 -8 37.5%
2020 -9 11.11%
2021 -12 18.18%
2022 -8 -57.14%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Concord Medical Services Holdings Limited Free Cashflow
Year Free Cashflow Growth
2008 15.199.000
2009 28.899.000 47.41%
2010 79.848.000 63.81%
2011 118.783.000 32.78%
2012 -25.222.000 570.95%
2013 99.032.000 125.47%
2014 380.531.000 73.98%
2015 -357.110.000 206.56%
2016 -200.051.000 -78.51%
2017 -269.825.000 25.86%
2018 -804.766.000 66.47%
2019 -896.848.000 10.27%
2020 -742.668.000 -20.76%
2021 -1.139.606.000 34.83%
2022 -1.153.317.000 1.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Concord Medical Services Holdings Limited Operating Cashflow
Year Operating Cashflow Growth
2008 46.774.000
2009 135.883.000 65.58%
2010 190.972.000 28.85%
2011 137.102.000 -39.29%
2012 259.515.000 47.17%
2013 259.033.000 -0.19%
2014 490.381.000 47.18%
2015 -175.138.000 380%
2016 -78.078.000 -124.31%
2017 26.732.000 392.08%
2018 -38.591.000 169.27%
2019 -195.347.000 80.24%
2020 -229.766.000 14.98%
2021 -359.313.000 36.05%
2022 -755.913.000 52.47%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Concord Medical Services Holdings Limited Capital Expenditure
Year Capital Expenditure Growth
2008 31.575.000
2009 106.984.000 70.49%
2010 111.124.000 3.73%
2011 18.319.000 -506.61%
2012 284.737.000 93.57%
2013 160.001.000 -77.96%
2014 109.850.000 -45.65%
2015 181.972.000 39.63%
2016 121.973.000 -49.19%
2017 296.557.000 58.87%
2018 766.175.000 61.29%
2019 701.501.000 -9.22%
2020 512.902.000 -36.77%
2021 780.293.000 34.27%
2022 397.404.000 -96.35%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Concord Medical Services Holdings Limited Equity
Year Equity Growth
2008 565.020.000
2009 2.153.748.000 73.77%
2010 2.301.835.000 6.43%
2011 2.038.096.000 -12.94%
2012 2.341.796.000 12.97%
2013 2.436.179.000 3.87%
2014 1.800.058.000 -35.34%
2015 1.433.789.000 -25.55%
2016 1.231.770.000 -16.4%
2017 1.014.918.000 -21.37%
2018 2.273.881.000 55.37%
2019 1.889.238.000 -20.36%
2020 2.400.830.000 21.31%
2021 2.743.721.000 12.5%
2022 2.015.657.000 -36.12%
2023 2.087.942.000 3.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Concord Medical Services Holdings Limited Assets
Year Assets Growth
2008 1.514.395.000
2009 2.443.865.000 38.03%
2010 2.667.044.000 8.37%
2011 2.393.446.000 -11.43%
2012 3.615.180.000 33.79%
2013 4.085.924.000 11.52%
2014 2.959.332.000 -38.07%
2015 3.599.804.000 17.79%
2016 3.228.603.000 -11.5%
2017 3.465.390.000 6.83%
2018 4.585.394.000 24.43%
2019 4.297.445.000 -6.7%
2020 5.334.538.000 19.44%
2021 6.229.951.000 14.37%
2022 6.004.934.000 -3.75%
2023 6.070.070.000 1.07%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Concord Medical Services Holdings Limited Liabilities
Year Liabilities Growth
2008 949.375.000
2009 290.117.000 -227.24%
2010 365.209.000 20.56%
2011 355.350.000 -2.77%
2012 1.273.384.000 72.09%
2013 1.649.745.000 22.81%
2014 1.159.274.000 -42.31%
2015 2.166.015.000 46.48%
2016 1.996.833.000 -8.47%
2017 2.450.472.000 18.51%
2018 2.311.513.000 -6.01%
2019 2.408.207.000 4.02%
2020 2.933.708.000 17.91%
2021 3.486.230.000 15.85%
2022 3.989.277.000 12.61%
2023 3.982.128.000 -0.18%

Concord Medical Services Holdings Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
10.81
Net Income per Share
-17.6
Price to Earning Ratio
-0.43x
Price To Sales Ratio
0.7x
POCF Ratio
-1.53
PFCF Ratio
-0.55
Price to Book Ratio
-0.18
EV to Sales
7.22
EV Over EBITDA
-5.87
EV to Operating CashFlow
-15.74
EV to FreeCashFlow
-5.67
Earnings Yield
-2.33
FreeCashFlow Yield
-1.83
Market Cap
0,33 Bil.
Enterprise Value
3,41 Bil.
Graham Number
130
Graham NetNet
-77.92

Income Statement Metrics

Net Income per Share
-17.6
Income Quality
0.28
ROE
0.48
Return On Assets
-0.01
Return On Capital Employed
-0.01
Net Income per EBT
0.57
EBT Per Ebit
1.67
Ebit per Revenue
-0.81
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.66
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-0.01
Gross Profit Margin
-0.16
Operating Profit Margin
-0.81
Pretax Profit Margin
-1.34
Net Profit Margin
-0.76

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-4.96
Free CashFlow per Share
-13.77
Capex to Operating CashFlow
1.78
Capex to Revenue
-0.82
Capex to Depreciation
-2.9
Return on Invested Capital
-0.3
Return on Tangible Assets
-0.16
Days Sales Outstanding
396.5
Days Payables Outstanding
85.77
Days of Inventory on Hand
49.58
Receivables Turnover
0.92
Payables Turnover
4.26
Inventory Turnover
7.36
Capex per Share
-8.81

Balance Sheet

Cash per Share
3,62
Book Value per Share
-42,67
Tangible Book Value per Share
15.52
Shareholders Equity per Share
-42.67
Interest Debt per Share
76.92
Debt to Equity
-1.74
Debt to Assets
0.54
Net Debt to EBITDA
-5.3
Current Ratio
0.68
Tangible Asset Value
0,68 Bil.
Net Current Asset Value
-3,23 Bil.
Invested Capital
-1.74
Working Capital
-0,36 Bil.
Intangibles to Total Assets
0.22
Average Receivables
0,45 Bil.
Average Payables
0,12 Bil.
Average Inventory
61460000
Debt to Market Cap
9.86

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Concord Medical Services Holdings Limited Dividends
Year Dividends Growth
2011 0
2014 2 100%
2015 1 0%

Concord Medical Services Holdings Limited Profile

About Concord Medical Services Holdings Limited

Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

CEO
Dr. Jianyu Yang
Employee
918
Address
Tower A, Global Trade Center
Beijing, 100013

Concord Medical Services Holdings Limited Executives & BODs

Concord Medical Services Holdings Limited Executives & BODs
# Name Age
1 Ms. Xun Liu
Financial Controller
70
2 Dr. Jianyu Yang
Chairman & Chief Executive Officer
70
3 Mr. Boxun Zhang
Chief Financial Officer
70

Concord Medical Services Holdings Limited Competitors